| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Rein Therapeutics, Inc.
13G/A
Amendment 2
RNTX · 00887A204
|
10.0% |
5/8/2026
Event 5/6/2026
|
|||
| Bios Fund I, LP | 2.1% | ||||
| Bios Capital Management, LP | 10.0% | ||||
| Bios Fund II, LP | 0.5% | ||||
| Bios Fund II QP, LP | 1.7% | ||||
| Bios Fund II NT, LP | 0.2% | ||||
| Bios Equity Partners, LP | 0% | ||||
| Bios Clinical Opportunity Fund, LP | 3.0% | ||||
| Bios Fund III QP, LP | 1.7% | ||||
| Bios Fund III NT, LP | 0.3% | ||||
| Bios Advisors GP, LLC | 10.0% | ||||
| Bios Fund III, LP | 0.3% | ||||
| Bios Equity Cof, LP | 2.2% | ||||
| Bios Equity Partners II, LP | 2.4% | ||||
| Bios Equity Partners III, LP | 2.2% | ||||
| Cavu Advisors, LLC | 10.0% | ||||
| Cavu Management, LP | 10.0% | ||||
| Leslie W. Kreis | 10.0% | ||||
| Aaron G.L. Fletcher | 10.0% | ||||
| Bios Fund I QP, LP | 1.2% | ||||
| Bios LTI Co-Invest III QP, LP | 5.5% | ||||
| Bios LTI Co-Invest III, LP | 5.4% | ||||
| Bios LTI SPV II, LP | 1.9% | ||||
| Bios 2026 Co-Invest, LP | 1.3% | ||||
| Bios 2024 Co-Invest, LP | 0.7% | ||||
|
Actuate Therapeutics, Inc.
13D/A
Amendment 2
ACTU · 005083100
|
49.8% |
6/30/2025
Event 6/27/2025
|
|||
| Bios Fund I, LP | 2.6% | ||||
| Bios Fund I QP, LP | 1.5% | ||||
| Bios Fund II, LP | 1.5% | ||||
| Bios Fund II QP, LP | 4.9% | ||||
| Bios Fund II NT, LP | 0.7% | ||||
| Bios Fund III, LP | 1.9% | ||||
| Bios Fund III QP, LP | 12.3% | ||||
| Bios Fund III NT, LP | 2.0% | ||||
| BP Directors, LP | 0.6% | ||||
| Bios Actuate Co-Invest I, LP | 1.5% | ||||
| Bios Actuate Co-Invest II, LP | 10.2% | ||||
| Bios Actuate Co-Invest III, LP | 2.8% | ||||
| Bios Clinical Opportunity Fund, LP | 6.2% | ||||
| Bios 2024 Co-Invest, LP | 1.3% | ||||
| Bios Equity Partners, LP | 4.6% | ||||
| Bios Equity Partners II, LP | 8.5% | ||||
| Bios Equity Partners III, LP | 29.2% | ||||
| Bios Equity Cof, LP | 7.4% | ||||
| Cavu Management, LP | 42.2% | ||||
| Bios Capital Management, LP | 49.5% | ||||
| Cavu Advisors, LLC | 42.2% | ||||
| Bios Advisors GP, LLC | 49.5% | ||||
| Leslie W. Kreis | 42.6% | ||||
| Aaron G.L. Fletcher | 49.8% | ||||
|
Actuate Therapeutics, Inc.
13D/A
Amendment 1
ACTU · 005083100
|
51.3% |
5/27/2025
Event 5/22/2025
|
|||
| Bios Fund I, LP | 2.7% | ||||
| Bios Fund I QP, LP | 1.6% | ||||
| Bios Fund II, LP | 1.6% | ||||
| Bios Fund II QP, LP | 5.1% | ||||
| Bios Fund II NT, LP | 0.7% | ||||
| Bios Fund III, LP | 2.0% | ||||
| Bios Fund III QP, LP | 12.8% | ||||
| Bios Fund III NT, LP | 2.1% | ||||
| BP Directors, LP | 0.6% | ||||
| Bios Actuate Co-Invest I, LP | 1.5% | ||||
| Bios Actuate Co-Invest II, LP | 10.7% | ||||
| Bios Actuate Co-Invest III, LP | 2.9% | ||||
| Bios Clinical Opportunity Fund, LP | 6.4% | ||||
| Bios 2024 Co-Invest, LP | 0.6% | ||||
| Bios Equity Partners, LP | 4.8% | ||||
| Bios Equity Partners II, LP | 8.9% | ||||
| Bios Equity Partners III, LP | 30.4% | ||||
| Bios Equity Cof, LP | 7.1% | ||||
| Cavu Management, LP | 44.0% | ||||
| Bios Capital Management, LP | 51.0% | ||||
| Cavu Advisors, LLC | 44.0% | ||||
| Bios Advisors GP, LLC | 52.4% | ||||
| Leslie W. Kreis | 44.4% | ||||
| Aaron G.L. Fletcher | 51.3% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.